Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Primary ITP is a rare, autoimmune disorder in which the immune system mistakenly targets and destroys platelets, the cells essential for blood clotting, leading to symptoms such as prolonged bleeding, easy bruising, and chronic fatigue.

Ianalumab plus eltrombopag, compared to placebo plus eltrombopag, significantly prolonged the time to treatment failure (TTF), the primary endpoint that assesses how long patients maintain safe platelet levels during and after treatment.

Ianalumab is being investigated in other B-cell-driven autoimmune diseases, including ongoing Phase 3 trials in first-line ITP and second and later lines of warm autoimmune hemolytic anemia, with readouts expected in 2026.

Also Read: FDA Eases Access To Life-Saving Gene Therapies For ...